The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis

Read full text
Authors: Yu Zhang, Yulin Ren, Xiang-Rui Song, Xi-jie He, Xiaoyu Wen
Cited by: 2
References: 46

Abstract

Objectives Drug-induced liver injury (DILI) is a recognized adverse drug event. Although most cases present with acute hepatic damage, evidence indicates that a proportion progress to persistent liver injury. The absence of a standardized definition for chronic DILI has contributed to significant discrepancies in reported incidence rates across clinical studies. This meta-analysis aims to determine the pooled incidence of chronic DILI, providing robust epidemiological evidence. Methods This meta-analysis was conducted in accordance with the PRISMA and MOOSE guidelines. A systematic search was conducted in PubMed, Web of Science, Embase and Cochrane Library databases from their respective inception dates to 11 July 2025. The quality of cohort studies was assessed using the NOS. A random-effects model was used to calculate the pooled incidence of chronic DILI, expressed as corresponding 95% confidence intervals ( CI s). Subgroup analyses were performed to explore potential sources of heterogeneity. Publication bias was assessed and sensitivity analyses were conducted. All statistical tests were two-tailed, and a P value

Fields of Study & Subjects

Drug-Induced Hepatotoxicity and Protection Poisoning and overdose treatments Chemotherapy-induced organ toxicity mitigation

Publication details

Journal / source
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Volume
17
Pages
1710414–1710414
Publication date
29 January 2026
Language
EN